Cargando…

Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis

BACKGROUND: Aspirin is widely used for prevention of cardiovascular disease. In recent years randomized trials also suggested a preventive effect for various types of cancer. We aimed to assess, in a quantitative way, benefits and harms of aspirin for primary prevention of both cardiovascular diseas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stegeman, Inge, Bossuyt, Patrick M., Yu, Tsung, Boyd, Cynthia, Puhan, Milo A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494891/ https://www.ncbi.nlm.nih.gov/pubmed/26151751 http://dx.doi.org/10.1371/journal.pone.0127194

Ejemplares similares

Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer
por: Puhan, Milo A., et al.
Publicado: (2015)

Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention()
por: Wang, Frances M., et al.
Publicado: (2023)

Net benefit of statins for primary prevention of cardiovascular disease in people 75 years or older: a benefit–harm balance modeling study
por: Yebyo, Henock G., et al.
Publicado: (2019)

Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
por: Puhan, Milo A., et al.
Publicado: (2015)

Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts
por: Yebyo, Henock G., et al.
Publicado: (2018)

Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study
por: Yebyo, Henock G., et al.
Publicado: (2020)

A framework for organizing and selecting quantitative approaches for benefit-harm assessment
por: Puhan, Milo A, et al.
Publicado: (2012)

Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment
por: Aschmann, Hélène E, et al.
Publicado: (2019)

Critical Overview on the Benefits and Harms of Aspirin
por: Kwok, Chun Shing, et al.
Publicado: (2010)

Aspirin for primary prevention of cardiovascular disease
por: Nansseu, Jobert Richie N., et al.
Publicado: (2015)

Aspirin for Primary Prevention of Cardiovascular Disease
por: Kim, Ji Hye, et al.
Publicado: (2019)

Large-scale prevention trials could provide stronger evidence for decision-makers: Opportunities to design and report with a focus on the benefit–harm balance
por: Aschmann, Hélène E, et al.
Publicado: (2022)

Aspirin overutilization for the primary prevention of cardiovascular disease
por: VanWormer, Jeffrey J, et al.
Publicado: (2014)

Aspirin for primary prevention of cardiovascular disease in diabetes
por: Xing, Ying, et al.
Publicado: (2019)

Aspirin for the primary prevention of cardiovascular disease in the elderly
por: O’Sullivan, Jack W
Publicado: (2019)

Aspirin in primary prevention of cardiovascular disease in diabetes
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2021)

Use of Aspirin and Statin as primary prevention for cardiovascular diseases
por: Alkhail, Bahaa Aba, et al.
Publicado: (2016)

Aspirin for Primary Prevention of Cardiovascular Diseases: “WALTZ” with the Evidence
por: Dimitriadis, Kyriakos, et al.
Publicado: (2022)

Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease
por: Chen, Yinong, et al.
Publicado: (2021)

Estimates of benefits and harms of prophylactic use of aspirin in the general population
por: Cuzick, J., et al.
Publicado: (2015)

Fingolimod versus interferon beta 1-a: Benefit–harm assessment approach based on TRANSFORMS individual patient data
por: Spanu, Alessandra, et al.
Publicado: (2022)

Aspirin for Prevention of Cardiovascular Disease
por: Mendy, Vincent L., et al.
Publicado: (2017)

Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit−risk ratio, not age
por: Kim, Kyungmann, et al.
Publicado: (2021)

Individualised benefit–harm balance of aspirin as primary prevention measure – a good proof-of-concept, but could have been better…
por: Thorat, Mangesh A.
Publicado: (2016)

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
por: Coccheri, Sergio
Publicado: (2017)

Should Aspirin Be Used for the Primary Prevention of Cardiovascular Disease in the General Population?
por: Huang, Qing-Yu, et al.
Publicado: (2015)

Which people should take aspirin for primary prevention of cardiovascular disease?
por: Lozano, Roberto, et al.
Publicado: (2015)

High prevalence of potential biases threatens the interpretation of trials in patients with chronic disease
por: Vollenweider, Daniela, et al.
Publicado: (2011)

Aspirin in people with dementia, long-term benefits, and harms: a systematic review
por: Davis, Katrina A. S., et al.
Publicado: (2021)

Informing Evidence-Based Decision-Making for Patients with Comorbidity: Availability of Necessary Information in Clinical Trials for Chronic Diseases
por: Boyd, Cynthia M., et al.
Publicado: (2012)

Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines
por: Yu, Tsung, et al.
Publicado: (2013)

Aspirin in the Modern Era of Cardiovascular Disease Prevention
por: Murphy, Ella, et al.
Publicado: (2021)

Iranian general populations' and health care providers' preferences for benefits and harms of statin therapy for primary prevention of cardiovascular disease
por: Saadati, Hassan, et al.
Publicado: (2020)

The Efficacy And Safety Of Aspirin As The Primary Prevention Of Cardiovascular Disease: An Updated Meta-Analysis
por: Xie, Wenchao, et al.
Publicado: (2019)

Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach
por: Cofer, Lucas B., et al.
Publicado: (2022)

Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis
por: Ma, Hua, et al.
Publicado: (2021)

Where is the supporting evidence for treating mild to moderate chronic obstructive pulmonary disease exacerbations with antibiotics? A systematic review
por: Puhan, Milo A, et al.
Publicado: (2008)

Underutilization of Aspirin Persists in US Ambulatory Care for the Secondary and Primary Prevention of Cardiovascular Disease
por: Stafford, Randall S, et al.
Publicado: (2005)

Use of Aspirin for Primary and Secondary Cardiovascular Disease Prevention in the United States, 2011–2012
por: Mainous, Arch G., et al.
Publicado: (2014)

Aspirin for primary prevention of stroke in individuals without cardiovascular disease—A meta-analysis
por: Judge, Conor, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fudnd329u2c83qt94kiqgucil7